TAKEDA PHARMACEUTICAL COMPANY LIMITED Takeda Pharmaceutical Company Limited Stock Börse Stuttgart
Equities
TKDA
US8740602052
Pharmaceuticals
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12 EUR | +0.84% |
|
-2.44% | -6.98% |
| Sales 2024 | 4,264B 27.08B 25.31B 37.2B | Sales 2025 * | 4,269B 27.11B 25.34B 37.24B | Capitalization | 6,499B 41.28B 38.58B 56.69B |
|---|---|---|---|---|---|
| Net income 2024 | 144B 915M 855M 1.26B | Net income 2025 * | 103B 655M 612M 899M | EV / Sales 2024 | 2.57 x |
| Net Debt 2024 | 4,386B 27.86B 26.04B 38.26B | Net Debt 2025 * | 4,189B 26.61B 24.86B 36.54B | EV / Sales 2025 * | 2.5 x |
| P/E ratio 2024 |
45.4
x | P/E ratio 2025 * |
64.1
x | Employees | 49,095 |
| Yield 2024 |
4.49% | Yield 2025 * |
4.69% | Free-Float | 99.12% |
More Fundamentals
* Assessed data
More news
Latest transcript on Takeda Pharmaceutical Company Limited
More recommendations
More press releases
More news
| 1 day | +0.84% | ||
| Current month | -11.11% | ||
| 6 months | -6.25% | ||
| Current year | -6.98% |
Current year
12.00
13.50
1 year
12.0013.50
3 years
12.0014.60
5 years
12.0018.70
10 years
12.0018.70
| Managers | Title | Age | Since |
|---|---|---|---|
Christophe Weber
CEO | Chief Executive Officer | 57 | 14-03-31 |
Gabriele Ricci
CTO | Chief Tech/Sci/R&D Officer | 45 | 22-01-31 |
Mwana Lugogo
CMP | Compliance Officer | 54 | 11-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 71 | 16-05-31 | |
Ian Clark
BRD | Director/Board Member | 62 | 18-12-31 |
Steven Gillis
BRD | Director/Board Member | 71 | 18-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-14 | 12 | +0.84% | 0 |
| 24-06-13 | 11.9 | -3.25% | 0 |
| 24-06-12 | 12.3 | 0.00% | 0 |
| 24-06-11 | 12.3 | -0.81% | 0 |
| 24-06-10 | 12.4 | +0.81% | 0 |
Delayed Quote Börse Stuttgart, June 14, 2024 at 02:11 am
More quotes
Takeda Pharmaceutical Company Limited specializes in the development, manufacturing and marketing of pharmaceutical products especially for metabolic and cardiovascular diseases, cancers and central nervous systems troubles. The activity is organized around 2 areas:
- sale of drugs and consumer care products;
- services.
Net sales are distributed geographically as follows: Japan (17.5%), Asia (5%), the United States (49%), Europe and Canada (20.8%), Latin America (3.8%), Russia and CIS (1.8%) and other (2.1%).
Sector
Pharmaceuticals
Calendar
2024-06-25
- Annual General Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
18
Last Close Price
4,142
JPY
Average target price
4,768
JPY
Spread / Average Target
+15.11%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +50.70% | 791B | |
| +41.96% | 630B | |
| -7.15% | 350B | |
| +18.77% | 328B | |
| +8.79% | 298B | |
| +18.02% | 246B | |
| +1.27% | 225B | |
| +11.95% | 218B | |
| +3.68% | 160B |
- Stock Market
- Equities
- 4502 Stock
- TKDA Stock
